Natcher Conference Center, Bethesda, MD

Response Definitions

Sub-Committee on Disease-Specific Methods And Strategies For Monitoring Relapse Following Allogeneic Stem Cell Transplantation

Natcher Conference Center, Bethesda, MD

Definitions: Goals

Working vs proposed vs research definitions

Define the following in regard to post-SCT setting

- -Response
- -Persistence
- -Progression
- -Relapse
- -Relapse prediction

Disease-specific

- -AML
- -MDS
- -ALL
- -Lymphoma
- -CML
- -CMPD
- -CLL
- -MM

Natcher Conference Center, Bethesda, MD

AML

Revised criteria: AML International Working Group (Cheson, JCO 2003)

| Parameters | Complete remission | Relapse |
|------------------------|--|-----------------------------|
| Morphological/ | BM blasts <5%; | Reappearance of blasts post |
| hematological criteria | platelets $\geq 100 \times 10^9 / L$; | CR in BM/PB |
| | neutrophils $\geq 1.0 \times 10^9 / L$ | |
| Cytogenetic criteria | Disappearance of | Reappearance of cytogenetic |
| | cytogenetic alteration | alteration |
| Molecular remission | Disappearance of molecular | Reappearance of molecular |
| | mutation | mutation |
| Flow cytometry | Disappearance of cells with | Reappearance of cells with |
| | previously determined LAIP | LAIP |

(BM: bone marrow; PB: peripheral blood; LAIP: leukemia associated immunophenotype)

Natcher Conference Center, Bethesda, MD

Discussion points

Deficiencies of current table

- No thresholds for "disappearance" or "reappearance"
- Impact of specific molecular markers vary
- Chimerism not included
- •? Cri
- •CIBMTR criteria
- •Issues uniform surveillance, methodology availability

Natcher Conference Center, Bethesda, MD

MDS

Revised criteria: MDS International Working Group

(Cheson, Blood 2006)

| Criteria of remission | Parameters | |
|------------------------|---|--|
| Morphologic and | Complete remission (CR): bone marrow blasts <5% without | |
| hematological response | dysplasia, hemoglobin $\ge 11 \text{ g/dL}$, platelets $\ge 100 \text{ x } 10^9 \text{/L}$, | |
| | neutrophils $\geq 1.5 \times 10^9 / L$ | |
| | Partial remission (PR): reduction of blasts by at least 50% or | |
| | achievement of lower risk category than prior to treatment | |
| Cytogenetic response | Major cytogenetic response: disappearance of a cytogenetic | |
| | abnormality. | |
| | Minor cytogenetic response: ≥50% reduction of abnormal | |
| | metaphases | |
| Quality of life | Clinical improvement in physical/social function and well-being | |
| Hematologic | Specific responses of cytopenias in the 3 hematopoietic lineages | |
| improvement | | |

Natcher Conference Center, Bethesda, MD

Discussion points

Deficiencies of current table

- No definitions for relapse
- No molecular definitions, chimerism
- •Clonal recurrences, (incl evolution)